The drugmakers have already committed more than half that capacity, BioNTech said in a presentation filed Monday. A more than 50% boost from the previous 2021 target of 1.3 billion doses, the increase incorporates a label change that will allow doctors to extract six doses instead of five from each vaccine vial, BioNTech said.
Vaccine supply has been under intense scrutiny as Europe faces a new, faster-spreading variant of the virus that first emerged in the U.K., with the European Union last week sealing a deal to double its supply of Pfizer-BioNTech shots to as many as 600 million.
A new production site in Marburg, Germany, expected to become operational by the end of February will be able to make as many as 750 million doses per year, according to the presentation. BioNTech said it’s also seeking to add suppliers and contract manufacturers and improve its production processes.